European interest in Wegovy expected to match US demand, says EVP at Novo Nordisk
According to Martin Holst Lange, executive vice president for development at Novo Nordisk, Wegovy is predicted to receive just as warm of a welcome outside the US as it did when it was launched there in June.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN
Expectations for the European launch of the weight loss drug Wegovy are sky-high after the pharmaceutical company announced on Thursday that the European Medicines Agency's expert committee, the CHMP, has given a positive opinion on the treatment.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novo Nordisk hopes to stabilize Wegovy supply in early 2022
For subscribers
